We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Medivolve, Inc. ("Medivolve" or the "Company") (NEO: MEDV) (OTC: COPRF) (FRA: 4NC) is pleased to announce a 236% increase in gross weekly revenues, driven by an influx of COVID-19 testing sales, proceeding the beta launch of the Company's new Electronic.